ESSENCE

A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study of Olezarsen (ISIS 678354) in Patients with Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), or with Severe Hypertriglyceridemia

Stage
klaar
Medicine
Olezarsen
Population
ASCVD
Phase
III
First Patient In
23 June 2023
Last Patient In
14 February 2024
Last Patient Last Visit
28 May 2025

National Lead

prof. dr. E.S.G. Stroes

Cardioloog

Study Director

drs. K.W. Wu

Cardioloog

Office Contact

S. Jansen

Studiemanager

The page has expired.